bioRxiv · 10.1101/470062
IL-11 neutralising therapies target hepatic stellate cell-induced liver inflammation and fibrosis in NASH
Abstract
The transformation of hepatic stellate cells (HSCs) into myofibroblasts is the defining pathobiology in non-alcoholic steatohepatitis (NASH). Here we show that key NASH factors induce IL-11, which drives an autocrine and ERK-dependent activation loop to initiate and maintain HSC-to-myofibroblast transformation, causing liver fibrosis. IL-11 is upregulated in NASH and Il11ra1-deleted mice are strongly protected from liver fibrosis, inflammation and steatosis in murine NASH. Therapeutic inhibition of IL11RA or IL-11 with novel neutralizing antibodies robustly inhibits NASH pathology in preclinical models and reverses established liver fibrosis by promoting HSC senescence and favourable matrix remodelling. When given early in NASH, IL-11 inhibition prevents liver inflammation and steatosis, reverses severe hepatocyte damage and reduces hepatic immune cells and TGF{beta}1 levels. Our findings show an unappreciated and central role for IL-11 in HSCs and prioritise IL-11 signalling as a new therapeutic target in NASH while revealing an unexpected pro-inflammatory function for IL-11 in stromal immunity.
Source connections
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Widjaja, A. A., Singh, B. K., Adami, E., Viswanathan, S., D'Agostino, G. A., Dong, J. R., Ng, B., Tan, J., Paleja, B. S., Tripathi, M., Lim, S. Y., Chothani, S., Lim, W. W., Rabes, A., Sombetzki, M., Bruinstroop, E., Sinha, R. A., Albani, S., Yen, P. M., Schafer, S., Cook, S. A.. 2018-11-14. IL-11 neutralising therapies target hepatic stellate cell-induced liver inflammation and fibrosis in NASH. https://doi.org/10.1101/470062
Cite the original work for its findings. Save a collection to share your selection of sources.